FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

407005009: Efalizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2004. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
2150835018 Efalizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
2158639014 Efalizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
193111000077117 efalizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
807981000172117 éfalizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Efalizumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Efalizumab (substance) Is a Immunosuppressant (substance) true Inferred relationship Some
Efalizumab (substance) Is a agent d'anticorps monoclonal false Inferred relationship Some
Efalizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. A substance that modifies the immune response or the functioning of the immune system. true Inferred relationship Some
Efalizumab (substance) Is a anticorps monoclonal chimérique souris-humain d'isotype IgG false Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing efalizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Efalizumab (substance) Inferred relationship Some 1
Raptiva The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Efalizumab (substance) Inferred relationship Some
Efalizumab 125mg/vial lyophilized powder for injection The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Efalizumab (substance) Inferred relationship Some
Raptiva 125mg/vial lyophilized powder for injection The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Efalizumab (substance) Inferred relationship Some
Efalizumab only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Efalizumab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start